CD79B(CD79b, B29, IGB, Ig-beta) (Polatuzumab biosimilar) Antibody from ABBEXA LTD
Search, find, compare suppliers for anti-CD79B(CD79b, B29, IGB, Ig-beta) (Polatuzumab biosimilar) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD79B(CD79b, B29, IGB, Ig-beta) (Polatuzumab biosimilar) |
| Clone | monoclonal |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | IgG1 kappa |
| Format | Protein A/G purified |
| Size | 100 µg, 1 mg, |
| Concentration | typically between 0.5-2.0 mg/ml. |
| Applications | ELISA, WB |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Polatuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD79B(CD79b, B29, IGB, Ig-beta), for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta, Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain. CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR). CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. |
| Immunogen | n/a |
| Other Names | Polatuzumab, CD79B(CD79b, B29, IGB, Ig-beta) |
| Gene, Accession # | n/a |
| Catalog # | abx831275 |
| Price | please inquire |
| Order / More Info | CD79B(CD79b, B29, IGB, Ig-beta) (Polatuzumab biosimilar) Antibody from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Antibodies